Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
CagriSema vs Wegovy HD: Which Is Better — and Which Can You Actually Get in 2026?
By The RX Index Editorial Team —
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
All data from FDA approval announcements, Novo Nordisk trial releases, and verified pricing sources. Educational information only, not medical advice.Bottom line: If you're comparing CagriSema vs Wegovy HD and want to know which one you can act on today, the answer is Wegovy HD. It's FDA-approved (March 19, 2026), available now, and runs about $399 a month self-pay. CagriSema is not approved in the U.S. yet — Novo Nordisk filed its application in December 2025, and a decision is expected in late 2026. On headline trial numbers, CagriSema averages about 22.7% weight loss and Wegovy HD about 20.7% — close, from two separate trials that were never head-to-head. This isn't really a “which one wins” question. It's a timing question: an option you can start now, or one you'd have to wait for.
Quick verdict: which one fits you?
Wegovy HD is the practical choice for anyone who needs an FDA-approved option now, especially people already on Wegovy 2.4 mg who have stalled. CagriSema is a promising future option that is still investigational in the U.S.
| If you are… | Best move | Why |
|---|---|---|
| Already on Wegovy 2.4 mg and stalled | Ask about Wegovy HD | FDA-approved and made for exactly this — people who need more after the standard dose |
| Brand new to GLP-1 medication | Start standard, not HD | Wegovy HD is not a starting dose — you'd begin lower and step up over time |
| Set on CagriSema specifically | Wait and watch | Not approved, no U.S. price, no FDA-approved path outside a clinical trial yet |
| Chasing the highest weight loss available today | Compare Wegovy HD and Zepbound | In a head-to-head trial, tirzepatide (Zepbound) edged out CagriSema: 25.5% vs 23.0% |
| Not sure what fits you | Take our free 60-second matching quiz | Points you to the right path in about a minute |
CagriSema vs Wegovy HD: the side-by-side facts
Verified May 30, 2026
CagriSema is an investigational once-weekly combination of cagrilintide and semaglutide that is not yet FDA-approved. Wegovy HD is an FDA-approved once-weekly 7.2 mg dose of semaglutide that launched nationwide in April 2026 at about $399 per month. The most important practical difference: one is available now, and one is not.
| Decision factor | CagriSema | Wegovy HD (7.2 mg) |
|---|---|---|
| U.S. status (May 2026) | ❌ Not approved. Application filed Dec 18, 2025; decision expected late 2026 | ✓ FDA-approved Mar 19, 2026 |
| Can you get it today? | No — only inside a clinical trial | Yes — launched nationwide Apr 7, 2026 through 70,000+ pharmacies and select telehealth |
| What it is | Two medicines in one shot: cagrilintide 2.4 mg + semaglutide 2.4 mg | Semaglutide 7.2 mg — the highest-dose Wegovy |
| How it works | GLP-1 (appetite) plus amylin (a second fullness hormone) | GLP-1 only, at triple the standard 2.4 mg dose |
| Average weight loss (stayed on it) | 22.7% at 68 weeks (REDEFINE 1) | 20.7% at 72 weeks (STEP UP) |
| Average weight loss (everyone who started) | 20.4% | 18.8% |
| Reached 25%+ weight loss (stayed on it) | 40.4% | 33.2% (about 1 in 3) |
| Head-to-head vs Zepbound | 23.0% vs Zepbound's 25.5% — CagriSema lost; missed its primary goal | Not tested head-to-head at 7.2 mg |
| Who it's for | (If approved) adults with obesity, or overweight plus a health condition | Adults who tolerated 2.4 mg for 4+ weeks and need more — a step-up dose, not a starter |
| Self-pay price (U.S.) | None — not for sale | ~$399/month |
| Compounded version available? | ❌ No — cagrilintide cannot be legally compounded under federal law (FDA statement) | N/A (brand-name only; no generic) |
| The pen | Not FDA-labeled yet; final U.S. device details unknown until approval | Simple single-dose pen |
Quick definitions: A GLP-1 receptor agonist copies a gut hormone that tells your brain you're full. An amylin analogue copies a second “I'm full” hormone made by the pancreas. CagriSema combines both. Wegovy HD uses only the GLP-1 type, at a higher dose.
Weight-loss figures come from two separate trials (REDEFINE 1 for CagriSema, STEP UP for Wegovy HD) with different designs. They are useful context, not a true head-to-head.
Sources: FDA Wegovy HD approval; REDEFINE 1 results (NEJM); Wegovy HD launch + STEP UP
Interactive Tool
Wait for CagriSema, or ask about Wegovy HD?
Answer 5 quick questions. You'll get a clear, personalized next step in under a minute. This is not medical advice and does not prescribe anything.
Where are you right now with Wegovy?
Can you actually get CagriSema or Wegovy HD right now?
| Medication | U.S. approval | Available now? | Your real next step |
|---|---|---|---|
| CagriSema | Application filed; not approved | No | Follow the FDA decision. Don't buy unapproved versions. |
| Wegovy HD | Approved Mar 19, 2026 | Yes, if prescribed | Ask a clinician if you qualify — usually after tolerating the 2.4 mg dose. |
What “not approved” means for CagriSema
No FDA-approved label. No set U.S. price. No FDA-approved way to fill a prescription outside a clinical trial. It's a real medicine with strong trial data — but for now, it lives in studies, not pharmacies.
What “FDA-approved” means for Wegovy HD
A clinician can prescribe it today if it fits you. Approval doesn't mean everyone qualifies, it doesn't promise insurance will cover it, and it doesn't mean zero side effects. It means a clear label, set dosing, and known warnings.
When is the CagriSema FDA decision expected?
Novo Nordisk says an FDA decision on CagriSema for weight management is anticipated by late 2026. A couple of things worth knowing: even the version people are excited about may not be final — Novo has a higher-dose CagriSema (cagrilintide 2.4 mg + semaglutide 7.2 mg) trial only starting in the second half of 2026. Second, an FDA “decision date” isn't a pharmacy date. Approval can take time to turn into something you can actually fill.
Not willing to wait until late 2026?
Is CagriSema better than Wegovy HD?
CagriSema is not clearly “better” than Wegovy HD, because the strongest numbers for each came from different trials. CagriSema reported a slightly higher average (22.7% vs 20.7%), but it has no FDA approval and no U.S. availability. Until there's a direct head-to-head, the honest takeaway is that CagriSema is the wait-and-watch option and Wegovy HD is the action-now option.
“CagriSema beats Wegovy by a mile” — usually a mix-up
Many comparisons stack CagriSema against standard Wegovy, which averages about 15% weight loss. Against that, CagriSema's 22.7% looks huge. But this page is about Wegovy HD — the 7.2 mg dose that averages about 20.7%. Compare CagriSema to the high dose, and the gap shrinks to roughly two percentage points. Using the broader estimands — counting everyone who started, not just those who stuck with it — it's 20.4% vs 18.8%. Close.
Why you can't just compare the numbers casually
| What we're comparing | CagriSema | Wegovy HD |
|---|---|---|
| Trial | REDEFINE 1 | STEP UP |
| Length | 68 weeks | 72 weeks |
| Who was in it | Obesity/overweight, no diabetes | Obesity, no diabetes |
| Comparison group | vs placebo | vs placebo and 2.4 mg |
| Approval status | Not approved | Approved |
The Zepbound asterisk
We do have one real head-to-head for CagriSema — and it's worth knowing. In the REDEFINE 4 trial, CagriSema went directly against Zepbound (tirzepatide) and lost: 23.0% for CagriSema vs 25.5% for Zepbound, and it missed its main goal of proving it was at least as good. So if maximum weight loss is your only priority, the strongest available option might not be Wegovy HD or CagriSema — it might be Zepbound. See our CagriSema vs Zepbound comparison.
How much weight did people actually lose on CagriSema vs Wegovy HD?
In CagriSema's REDEFINE 1 trial, people lost 22.7% of their body weight at 68 weeks if they stayed on treatment, and 20.4% counting everyone who started. In Wegovy HD's STEP UP trial, people lost 20.7% at 72 weeks if they stayed on it, 18.8% counting everyone, and about one in three lost 25% or more.
People with obesity (no diabetes)
| Result | CagriSema (REDEFINE 1) | Wegovy HD (STEP UP) |
|---|---|---|
| Length | 68 weeks | 72 weeks |
| People in the trial | 3,417 | 1,407 |
| Average loss (stayed on it) | 22.7% | 20.7% |
| Average loss (everyone who started) | 20.4% | 18.8% |
| Lost 25% or more (stayed on it) | 40.4% | 33.2% |
One CagriSema stat stands out: about half (50.7%) of people with obesity in REDEFINE 1 dropped below the obesity line (a BMI under 30) by the end, starting from an average BMI of 38. About 23.1% lost 30% or more.
People with type 2 diabetes
| Result | CagriSema (REDEFINE 2) | Wegovy HD (STEP UP T2D) |
|---|---|---|
| Average loss (stayed on it) | about 15.7% | about 14.1% |
What's the real difference between CagriSema and Wegovy HD?
CagriSema combines two medicines — cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist) — in one weekly shot. Wegovy HD is not a combination; it's a higher 7.2 mg dose of semaglutide alone. A different approach doesn't automatically mean better results for any one person.
CagriSema = teamwork
Semaglutide copies your GLP-1 “I'm full” signal. Cagrilintide adds a second signal (amylin) that also curbs hunger. Two pathways, one shot. Final U.S. device details are not known until FDA approval.
Wegovy HD = a bigger dose of a known drug
Same semaglutide in regular Wegovy, just stronger (7.2 mg instead of 2.4 mg). No new molecule. The same simple single-dose pen people already know.
Does a different mechanism win? Not always. A higher dose isn't automatically right for everyone — stronger appetite control can also mean stronger side effects. That's a conversation for you and a clinician.
Who is Wegovy HD actually for?
Wegovy HD is not a starting dose. The FDA label says the 7.2 mg dose is for adults who have tolerated the 2.4 mg dose for at least 4 weeks and still need more weight loss. For most people following the normal step-up schedule, that's week 21 at the earliest.
Wegovy HD is likely a good fit if you:
- ✓Are already on the Wegovy injection
- ✓Have handled the 2.4 mg dose for at least a month
- ✓Still have meaningful weight to lose
- ✓Have talked through side effects and risks with a clinician
- ✓Know your cost before you step up
Wegovy HD is probably not your move if you:
- ❌Are brand new to semaglutide (start low and build up)
- ❌Aren't tolerating 2.4 mg well
- ❌Want to skip the step-up and jump to the strongest dose
- ❌Want CagriSema specifically -- it isn't available
Five questions worth asking your clinician:
- Have I been on 2.4 mg long enough to step up?
- Is more weight loss the right goal for me?
- What side effects should I watch for at 7.2 mg?
- Would Zepbound or another approved option make more sense for me?
- What will this actually cost with my insurance or cash?
FDA-Approved Access
Does this sound like your situation?
Check whether Wegovy HD (or another FDA-approved option) fits you on Ro. A clinician reviews your information and checks coverage.
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
What does Wegovy HD cost — and what will CagriSema cost?
Wegovy HD 7.2 mg runs about $399 per month self-pay. People with commercial insurance that covers Wegovy may pay much less. CagriSema has no U.S. price because it isn't approved yet.
| Route | What they advertise | What we verified (May 30, 2026) | Best for |
|---|---|---|---|
| NovoCare Pharmacy (direct self-pay) | $399/month | $399/month | Lowest cash price, no membership |
| Commercial insurance + savings offer | “as little as $25/month” | As little as $25/month (up to $100/month savings cap; government plans excluded) | People whose plan covers Wegovy |
| Ro — medication | $399/month, less on prepay | $399 cash, or $329 (3-month) / $299 (6-month) / $249 (annual) | Prepay savings + support |
| Ro — membership | Starts at $39 | $39 first month, then $74/month (annual) or $149/month (monthly) — billed separately from medication | Add-on for clinician + insurance help |
| CagriSema | — | No U.S. price (not approved) | Not available |
Can you get a “compounded” version of CagriSema?
⚠ No — and this one matters for your safety
The FDA states that cagrilintide cannot be used in compounding under federal law, and it has not been found safe or effective for any use. “Compounded CagriSema,” loose “cagrilintide,” and research-chemical versions sold online are unapproved and potentially dangerous. The FDA has sent warning letters to companies distributing these ingredients.
- ✓Compounded semaglutide is its own separate, debated category (and not what this page is about).
- ❌Cagrilintide cannot legally be compounded at all. It isn't part of any FDA-approved drug, and the FDA has warned companies selling it.
The only legitimate routes: start an approved option now (like Wegovy HD), wait for CagriSema to clear the FDA, or ask your doctor about joining a clinical trial. Rolling the dice on an unregulated vial is not a fourth option.
Which one has more side-effect risk or uncertainty?
Both are semaglutide-based (or contain semaglutide), so the most common side effects are stomach-related — nausea, vomiting, and constipation — usually mild to moderate. Wegovy HD has a full FDA label with known warnings and a specific higher-dose signal for altered skin sensation, while CagriSema has trial safety data but no final U.S. label yet.
CagriSema (REDEFINE 1)
- GI side effects overall: 79.6% vs 39.9% placebo
- Nausea: 55% · Constipation: 30.7% · Vomiting: 26.1%
- Quit due to side effects: about 6% vs ~3.7% placebo
- Most were mild-to-moderate and faded over time.
Wegovy HD — FDA label
- Nausea: 39% HD / 35% 2.4 mg / 13% placebo
- Vomiting: 22% / 16% / 6%
- Constipation: 20% / 19% / 8%
- Dysesthesia (skin tingling): 22% at 7.2 mg vs 6% at 2.4 mg vs 0.3% placebo
- Quit due to adverse reactions: 5% (HD) / 5% (2.4 mg) / 2% placebo
Boxed warning that applies to all Wegovy doses
Wegovy carries a boxed warning — the FDA's most serious type — about a possible risk of thyroid tumors based on animal studies. It should not be used by anyone with a personal or family history of medullary thyroid cancer, or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Other serious warnings include pancreatitis, gallbladder problems, dehydration-related kidney injury, severe GI reactions, low blood sugar with insulin/sulfonylureas, diabetic-retinopathy complications, hypersensitivity, faster heart rate, aspiration risk during surgery/sedation, and pregnancy precautions. Review the prescribing information and talk to a licensed clinician before starting or increasing the dose.
Quick map of the main concerns
| Side effect / risk | Why it matters | What to ask your clinician |
|---|---|---|
| Nausea, vomiting, constipation | Most common; usually mild-to-moderate and worst during dose increases | How to ease it, and how fast to step up |
| Altered skin sensation | More common at 7.2 mg (22% vs 6%); FDA is still studying it | What to watch for, and when to lower the dose |
| Dehydration / kidney strain | Heavy vomiting or diarrhea can hurt the kidneys | When to pause the dose and rehydrate |
| Thyroid warning (boxed) | Off-limits with MTC or MEN2 history | Whether your family history rules it out |
| Gallbladder / pancreas | Possible with fast weight loss and GLP-1s | Which warning signs should prompt a call |
How does CagriSema vs Wegovy HD compare to Zepbound?
Zepbound matters because CagriSema was already tested directly against it. In the REDEFINE 4 head-to-head trial, CagriSema reached 23.0% weight loss versus 25.5% for tirzepatide (Zepbound) and did not prove it was at least as good. So if you're shopping for the highest weight loss you can get today, Zepbound deserves a spot on your list.
| Option | Status | Average weight loss | Notes |
|---|---|---|---|
| Zepbound (tirzepatide) | FDA-approved, available | 25.5% | Beat CagriSema head-to-head in REDEFINE 4 |
| Wegovy HD (7.2 mg) | FDA-approved, available | 20.7% | Natural step-up if already on Wegovy |
| CagriSema | Not approved, not available | 22.7% | Strong but came up short vs Zepbound |
For many people, the choice between Wegovy HD and Zepbound comes down to which one you've tolerated, what your clinician recommends, and what your coverage allows. Read our Zepbound vs Wegovy comparison for the full picture.
Should you wait for CagriSema or start Wegovy HD now?
If you need an approved option now and already tolerate Wegovy 2.4 mg, asking a clinician about Wegovy HD is the practical move. If you're stable, not yet eligible for the high dose, or mainly curious about future medicines, CagriSema is worth tracking — but not waiting on as if it were already here.
Run yourself through this — takes 20 seconds
- Are you taking Wegovy 2.4 mg now?
- No → Wegovy HD probably isn't your starting point. Start with our quiz.
- Yes → keep going.
- Have you tolerated 2.4 mg for at least 4 weeks?
- No → sort out tolerance first with your clinician.
- Yes → keep going.
- Do you still have meaningful weight to lose?
- No → this may be a “maintain” conversation, not a step-up.
- Yes → keep going.
- What's your bigger concern — side effects or cost?
- Side effects → compare doses and options with a clinician.
- Cost → check insurance, NovoCare, and Ro before deciding.
- Are you only interested in CagriSema?
- → Track the FDA decision. There is no safe way to buy CagriSema early — no approved path today, and no safe shortcut.
The straight verdict
- ✓Talk to a clinician about Wegovy HD now if you're on 2.4 mg, tolerating it, and need more.
- ⓘTrack CagriSema if you're researching the future — just don't wait empty-handed.
- △Compare Zepbound if you want the strongest available option.
- ☼Take our quiz if any of this still feels foggy.
How we compared CagriSema and Wegovy HD
| Claim | What we found |
|---|---|
| Wegovy HD approval | Approved March 19, 2026 |
| Wegovy HD is a step-up dose | After 2.4 mg for 4+ weeks |
| Wegovy HD weight loss | 20.7% / 18.8%; ~1 in 3 lost ≥25% |
| CagriSema weight loss | 22.7% / 20.4% |
| CagriSema vs Zepbound | 23.0% vs 25.5%; missed its goal |
| Cagrilintide compounding | Cannot be legally compounded |
| Wegovy HD price | ~$399/month |
Frequently asked questions
Quick answers to the questions people search most about CagriSema and Wegovy HD.
Is CagriSema FDA-approved?
No. As of late May 2026, CagriSema is not approved in the U.S. for weight loss. Novo Nordisk filed the application in December 2025, and an FDA decision is expected in late 2026.
Is Wegovy HD FDA-approved?
Yes. The FDA approved Wegovy HD, the 7.2 mg higher dose of semaglutide, on March 19, 2026, for certain adults who need weight loss and long-term weight maintenance.
Can you start on Wegovy HD?
No. It is not a starting dose. The label says you can move up to 7.2 mg only after tolerating the 2.4 mg dose for at least 4 weeks, which is usually week 21 at the earliest.
Is CagriSema stronger than Wegovy HD?
Not proven. CagriSema averaged 22.7% weight loss in its trial and Wegovy HD averaged 20.7% in a separate trial. They were never tested head-to-head, so neither has been shown to win.
How much does Wegovy HD cost?
About $399 per month self-pay, according to Wegovy's cost page. People with commercial insurance that covers Wegovy may pay much less, sometimes as little as $25 a month (up to a $100 per month savings cap; government plans are excluded).
How much will CagriSema cost?
Unknown. CagriSema is not approved or for sale, so there is no real U.S. price yet.
Can I buy compounded CagriSema or cagrilintide?
No. The FDA states that cagrilintide cannot be legally compounded and that it has not been shown safe or effective. Avoid any seller offering it.
Should I wait for CagriSema or start Wegovy HD now?
If you need treatment now and already tolerate Wegovy 2.4 mg, asking a clinician about Wegovy HD is the practical move. If you are stable or only researching, CagriSema is worth tracking but not waiting on as if it were available.
Is CagriSema the same as Wegovy?
No. CagriSema combines cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist). Wegovy HD is semaglutide only, at a higher 7.2 mg dose. Different mechanism, different molecule count.
I'm stalled on Wegovy 2.4 mg -- what should I do?
Ask your clinician whether the stall is about dose, tolerance, habits, or something else, and whether Wegovy HD or another approved option fits. Wegovy HD is relevant only if you tolerate 2.4 mg and still need more weight loss.
Still not sure which GLP-1 program is right for you?
Our free 60-second quiz matches you to the right path based on your current medications, goals, and situation — whether that's Wegovy HD, Zepbound, a different option, or tracking CagriSema.
Take the free 60-second matching quiz →Related guides
- CagriSema vs Zepbound: Head-to-Head Trial Results (2026)
- CagriSema FDA Approval Status Tracker (2026)
- CagriSema vs Wegovy (Standard Dose) Comparison
- Wegovy HD Side Effects: 7.2 mg vs 2.4 mg (2026 FDA Data)
- Wegovy HD vs Wegovy: Should You Switch?
- Is Wegovy Safe? FDA Risks, Side Effects, and Who Should Avoid It
- Zepbound vs Wegovy: Full Comparison
Sources
- U.S. FDA — FDA Approves Higher Dose Semaglutide (Wegovy HD), March 19, 2026.
- U.S. FDA — FDA's Concerns with Unapproved GLP-1 Drugs (cagrilintide cannot be used in compounding).
- U.S. FDA — Wegovy Prescribing Information (215256s029lbl.pdf), revised March 2026.
- Novo Nordisk / NEJM — REDEFINE 1 results (22.7%, NEJM), June 2025.
- Novo Nordisk — REDEFINE 4 head-to-head vs tirzepatide (23.0% vs 25.5%), February 23, 2026.
- Novo Nordisk — CagriSema NDA filing, December 18, 2025.
- Novo Nordisk — Wegovy HD U.S. launch + STEP UP results, April 7, 2026.
- Wharton S, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13(11):949–963.
- Wegovy cost page: wegovy.com/obesity/what-to-pay-for-wegovy.html and Ro Wegovy HD page.
Disclosure: Some links on this page are affiliate links. If you start care through one, we may earn a commission at no extra cost to you. See our affiliate disclosure for details. This page is educational information, not medical advice. All figures verified from FDA approval announcements, Novo Nordisk trial releases, and manufacturer pricing sources.